By Paul Knoepfler Lakshmi Bharadwaj contributed to this article. See updated stem cell journal list for 2018 here. Important update on April 22, 2016. There are an increasing number of predatory journals out there and some use “stem cells” as a hook. This list is not an endorsement of these journals and in fact on […]
The Definitive Stem Cell Journal List Read More »
The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal,
Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »
I’m really looking forward to this Saturday’s Berkeley Stem Cell Meeting. You should go! Tickets are just $5 and the lineup is great. This looks to be one of the best stem cell meetings in Northern California this year. Below is my interview with the organizers giving some background and perspectives on the meeting. 1.
Interview With Organizers of Tomorrow’s Berkeley Stem Cell Meeting Read More »
Nominations for Stem Cell Person of the Year 2013 closed last night and I ended up with a remarkable list of 30 nominees. I have included a few sentences about each one below, often taking verbiage directly from the nominator. The online voting on these nominees will start soon. The top vote getters will move
BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall
Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program Read More »
Here is a comprehensive listing of the top stem cell meetings and conferences for 2014. My listing of these meetings is not an endorsement of them, but is provided for informational purposes so I am being as inclusive as possible. If you want me to post your meeting, email me or post a comment (I’ll delete
Stem Cell Meetings & Conferences 2014 Read More »
Late in 2012 I did a piece on the global trends in stem cell clinical trial patterns. It is time for an update. Another look at stem cell clinical trials now (late Sept. 2013) based on the clinicaltrials.gov database shows an encouraging trend. Total Stem Cell Clinical Trials The total number of stem cell clinical
Maps of global stem cell clinical trial trends Read More »
ABC News just reported that the FDA is allgedly “cracking down” on the publicly traded company, MiMedx (MDXG), which sells a placental derivative touted for healing powers. The Wall Street Journal is also following the story. According to ABC News: MiMedx is a publically traded, for-profit company that takes donated human placentas — solicited via a website featuring
MiMedx (MDXG) placental “stem cell magnet” drugs attract FDA attention and lawsuit Read More »
Lately on average patients or patient relatives contact me about stem cells more than once a week. That’s about 50 times a year. The patients or their parents have questions about stem cells most often. Sometimes they have comments about this blog. Other times they ask for medical advice from me. Because I am a
Contemplating patients contacting me about stem cells Read More »
Somewhere out in the ocean there is a container ship steaming from Singapore here to the US and getting close to our shores and on that ship are the first printing copies of my new book, Stem Cells: An Insider’s Guide. At the same time, preparations for the e-book version are just about done. I
Stem Cells: An Insider’s Guide Book Signing & Talk on October 10th Read More »